NeOnc Technologies Announces August 12 Conference Call To Present Topline Phase 2a Results From NEO100-01 Trial Of Intranasal NEO100 In IDH1-Mutant Glioma
Share
Why It Matters
NeOnc is sharing early test results for a new medicine designed to fight brain tumors on August 12. When companies announce results, you can watch how doctors and investors react to see if the medicine is working as hoped.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.